Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.

@article{Veenstra2007CosteffectivenessOP,
  title={Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.},
  author={David L. Veenstra and Sean D. Sullivan and Geoffry M Dusheiko and Michael Jacobs and Julia E Aledort and Gavin A Lewis and Kavita K. Patel},
  journal={European journal of gastroenterology & hepatology},
  year={2007},
  volume={19 8},
  pages={631-8}
}
BACKGROUND Peginterferon alpha-2a (40 kDa), a new treatment for chronic hepatitis B, produces seroconversion within 48 weeks in approximately 32% of HBeAg-positive patients. Over a defined treatment duration it offers improved efficacy over lamivudine, but at higher cost. We assessed the clinical outcomes and costs, from the perspective of the UK National Health Service, of 48 weeks of peginterferon alpha-2a (40 kDa) vs. 4 years of lamivudine. METHODS Cost-effectiveness was analysed using a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…